Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro).

Weight-loss injections known as GLP-1 receptor agonists could nearly halve the risk of obesity-related cancers, according to new research presented at the European Congress on Obesity in Malaga ...

It’s a once-a-week injection that reduces appetite and promotes weight loss. This version of the injectable GLP-1 drug contains a higher dose of semaglutide, and it’s FDA-approved for weight loss.

GLP1 agonist drugs, commonly known by brand names such as Ozempic and Mounjaro, reduce asthma symptoms in obese people ...

Currently, most GLP-1s are injections used to treat Type 2 diabetes. A few, including Wegovy, Zepbound, and Saxenda (liraglutide), are FDA-approved for weight loss.

Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro).